Tenapanor (XPHOZAH)
Hyperphosphatemia in chronic kidney disease patients on dialysis
Key Facts
Indication
Hyperphosphatemia in chronic kidney disease patients on dialysis
Phase
Approved
Status
Commercial
Company
About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company pioneering novel, targeted therapies for cardiorenal and metabolic conditions. The company has achieved significant milestones with two FDA-approved products, XPHOZAH for hyperphosphatemia in dialysis patients and IBSRELA for IBS-C, both based on its NHE3 sodium transporter inhibition platform. Ardelyx continues to advance its pipeline while commercializing its approved therapies, positioning itself at the intersection of nephrology, cardiology, and gastroenterology. The company's strategy focuses on addressing significant unmet medical needs through its unique mechanism of action.
View full company profile